Reducing Tobacco Harm: Don't Ban E-Cigarettes in Malaysia

Aug.01.2022
Malaysia's Generation Endgame plan aims to ban tobacco and e-cigarette sales to those born after 2007, but caution is needed.

It is often said that the road to hell is paved with good intentions. A prime example of this can be found in Malaysia's Ministry of Health's Generation Endgame plan, which prohibits the sale of tobacco and e-cigarette products to anyone born after 2007.


Given the widespread existence of illegal cigarettes in this country, the proposed ban, while understandable, should be approached with caution. History has repeatedly shown that measures similar to those seen during Prohibition not only fail to achieve their goals, but ultimately have the opposite effect. This includes fueling demand for unregulated and illicit products and services, as well as the syndicates behind them. Even more concerning is the fact that Generation Endgame, which includes e-cigarette products, suggests that people are willfully ignoring scientific and evidence-based strategies to curb smoking.


Electronic cigarettes have emerged as one of the most effective tools in reducing the harm caused by tobacco. This is not a wild claim, but a fact supported by a growing body of international research. Let's be clear. Electronic cigarettes are not without risk, but they have been proven to be far less harmful than smoking and more effective in helping smokers quit. Strategies to reduce harm are not new to Malaysia, as they have been shown to be effective in addressing HIV infection.


In 2006, the government introduced a needle exchange program and methadone substitution therapy. According to Professor Adeeba Kamarulzaman, Chair of the International AIDS Society, these harm reduction measures prevented as many as 13,317 new HIV infections or up to 39% between 2006 and 2013. She estimates that harm reduction programs will further reduce new HIV infections in Malaysia by 87% and save RM 209.5 million in healthcare costs from 2013 to 2023.


If we can recognize the value of reducing HIV cases, why can't we recognize the value of reducing harm from smoking? We don't need to reinvent the wheel. The UK and New Zealand have already paved the way for reducing tobacco harm. The government should not take the disastrous path of prohibition, but instead treat reducing tobacco harm as an asset and begin providing harm reduction training to healthcare professionals, particularly general practitioners, to reach the masses and assist smokers in quitting this habit for good.


Dr. Kumar Subaramaniam is a practicing physician with 25 years of experience. He has worked extensively in the psychiatric departments of various local hospitals and has a special interest in mental health. Over the years, Dr. Kumar has provided supportive counseling to patients, particularly in the realm of health counseling, and has given multiple public lectures on the subject of health.


Sorry, I cannot translate text without being provided with the original text that needs to be translated. Please provide me with the original text, and I'll be happy to help you with the translation.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan Industrial Co., Ltd. has filed a patent application for a cellulose-free scaffold material for nicotine pouches, proposing a combination of bioceramic material, polydextrose and sugar alcohols to replace conventional microcrystalline cellulose and cellulose derivatives. The filing aims to address issues including powdery mouthfeel, residue and limited release control, while also reducing reliance on existing cellulose-based patent portfolios. In patent examples, one fast-release formulation reached a nicotine release rate of 50% at 10 minutes and more than 90% at 20 minutes.
Sep.02
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
STIIIZY Redesign Fails to Escape PAX Labs Patent Import Ban as Section 337 Case Also Involves China ALD
U.S. Customs and Border Protection ruled that STIIIZY had not shown that the redesigned cannabis-vape products covered by its latest request fall outside an ITC limited exclusion order tied to PAX Labs patents. CBP accepted some of STIIIZY’s claim-construction and non-infringement arguments, but the company did not address two additional claims in the same patent. Earlier STIIIZY redesigned cartridges and certain associated components imported with them had received separate CBP clearance.
Sep.16
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
Former BAT global content lead Andy Parton has left the company and launched Destreza, a London-based AI-native marketing consultancy. Parton previously worked across BAT's New Category brands Vuse, Velo and glo and had also served as Global Brand Lead for Vuse Go. Destreza says it will advise consumer businesses on AI in brand strategy, operating models, capability and agency configuration, using specialist AI agents to support research, strategy and creative development. BAT reported £3.621 billion in New Category revenue in 2025.
Sep.22
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
New Zealand Associate Health Minister Casey Costello Warns on Illicit Cigarettes as Legal Tobacco Sales Halve Over Decade
New Zealand Associate Health Minister Casey Costello Warns on Illicit Cigarettes as Legal Tobacco Sales Halve Over Decade
New Zealand Associate Health Minister Casey Costello said legal tobacco sales in the country have fallen by more than half over the past decade, with sales declining more than 20% in 2025 compared with the previous year. She warned that the decline may not fully reflect lower smoking rates, as increased availability of illicit cigarettes could also be contributing. The government said it would continue strengthening tobacco and vape retail enforcement while monitoring the impact of illicit tobacco on public health and tax revenue.
Aug.26
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30